StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Candel Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $49.13M, up 131.3% year over year. For fiscal 2025 it was $30.50M, up 57.9% from the year before. The highest annual figure on record is $30.50M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.50M+57.9%
FY2024Dec 31, 2024$19.31M-21.2%
FY2023Dec 31, 2023$24.51M+17.9%
FY2022Dec 31, 2022$20.79M+37.0%
FY2021Dec 31, 2021$15.18M+73.4%
FY2020Dec 31, 2020$8.75M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.80M+183.2%
Q1 FY2026Mar 31, 2026$9.84M+145.0%
Q4 FY2025Dec 31, 2025$11.03M+128.9%
Q3 FY2025Sep 30, 2025$8.46M+56.2%
Q2 FY2025Jun 30, 2025$6.99M+40.4%
Q1 FY2025Mar 31, 2025$4.02M-2.1%
Q4 FY2024Dec 31, 2024$4.82M-33.6%
Q3 FY2024Sep 30, 2024$5.42M-7.3%
Q2 FY2024Jun 30, 2024$4.98M-16.1%
Q1 FY2024Mar 31, 2024$4.10M-25.0%
Q4 FY2023Dec 31, 2023$7.26M+46.0%
Q3 FY2023Sep 30, 2023$5.85M+8.7%
Q2 FY2023Jun 30, 2023$5.93M+18.2%
Q1 FY2023Mar 31, 2023$5.47M+1.0%
Q4 FY2022Dec 31, 2022$4.97M+29.0%
Q3 FY2022Sep 30, 2022$5.38M+2.1%
Q2 FY2022Jun 30, 2022$5.02M+52.6%
Q1 FY2022Mar 31, 2022$5.42M+96.8%
Q4 FY2021Dec 31, 2021$3.85M+9.1%
Q3 FY2021Sep 30, 2021$5.27M+190.4%
Q2 FY2021Jun 30, 2021$3.29M+83.4%
Q1 FY2021Mar 31, 2021$2.75M–
Q4 FY2020Dec 31, 2020$3.53M–
Q3 FY2020Sep 30, 2020$1.81M–
Q2 FY2020Jun 30, 2020$1.80M–

More Candel Therapeutics figures

See a number that looks wrong?